Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Thermo Fisher ( (TMO) ) is now available.
On February 12, 2026, Thermo Fisher Scientific issued a total of $3.8 billion in senior unsecured notes across four tranches maturing between 2031 and 2046, with coupons ranging from 4.215% to 5.546%. The notes, which are equal in ranking to the company’s other unsecured, unsubordinated debt and subject to standard covenants and change-of-control protections, were sold in a registered public offering under an existing indenture structure.
The company expects net proceeds of about $3.76 billion, primarily earmarked to fund a portion of the cash consideration for its previously announced acquisition of Clario Holdings, Inc., subject to customary regulatory and closing conditions. Pending completion of that deal, Thermo Fisher may temporarily allocate the funds to general corporate purposes or short-term investments, underscoring its ongoing use of the debt markets to support strategic M&A and balance sheet flexibility.
The most recent analyst rating on (TMO) stock is a Buy with a $670.00 price target. To see the full list of analyst forecasts on Thermo Fisher stock, see the TMO Stock Forecast page.
Spark’s Take on TMO Stock
According to Spark, TipRanks’ AI Analyst, TMO is a Neutral.
The score is driven primarily by solid underlying profitability and cash generation, tempered by slower growth, margin compression, and higher leverage. Earnings-call guidance is constructive with expected organic acceleration, EPS growth, and margin expansion, while technical momentum is currently soft and valuation (high P/E, low yield) is a notable headwind.
To see Spark’s full report on TMO stock, click here.
More about Thermo Fisher
Thermo Fisher Scientific Inc. is a global leader in the life sciences and laboratory equipment industry, providing analytical instruments, laboratory products, specialty diagnostics and biopharma services to pharmaceutical, biotech, academic and industrial customers. The company focuses on enabling scientific research, clinical diagnostics and applied markets through high-value technology and service offerings.
Average Trading Volume: 2,040,854
Technical Sentiment Signal: Buy
Current Market Cap: $202.8B
See more data about TMO stock on TipRanks’ Stock Analysis page.